Cardinal Health (NYSE:CAH) said today that it closed its $320 million all-cash acquisition of AccessClosure and its Mynx extravascular closure technology.

The Mynx biodegradable sealant products are designed to close off the femoral artery and then dissolve within 30 days.

"We’re excited about the AccessClosure acquisition, because it’s another great example of innovating to provide solutions and cost savings to the health care industry," Cardinal Health medical segment CEO Don Casey said in prepared remarks. "This acquisition is aligned to the company’s targeted growth areas, and we’re looking forward to similar opportunities for further expansion."

The deal, 1st announced last month, is expected to have "minimal impact" on adjusted earnings in 2014 and add slightly to Cardinal Health’s fiscal 2015 profits, according to a press release. AccessClosure put up more than $80 million in sales last year, Cardinal Health said.

AccessClosure’s technology has been at the heart of a patent infringement lawsuit with St. Jude Medical (NYSE:STJ). AccessClosure notched a couple of wins, most recently when a federal court in December 2013 refused to hear St. Jude’s patent infringement claim over the artery closure devices.

CAH shares had bumped up 1.2% today to $65.19 apiece as of about 11:10 a.m.